Volume 1319, Issue 1 p. 47-65
Original Article

Myeloid-derived suppressor cell heterogeneity in human cancers

Samantha Solito

Samantha Solito

Department of Surgery, Oncology and Gastroenterology, Oncology and Immunology Section, University of Padova, Padova, Italy

Search for more papers by this author
Ilaria Marigo

Ilaria Marigo

Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy

Search for more papers by this author
Laura Pinton

Laura Pinton

Department of Surgery, Oncology and Gastroenterology, Oncology and Immunology Section, University of Padova, Padova, Italy

Search for more papers by this author
Vera Damuzzo

Vera Damuzzo

Department of Surgery, Oncology and Gastroenterology, Oncology and Immunology Section, University of Padova, Padova, Italy

Search for more papers by this author
Susanna Mandruzzato

Corresponding Author

Susanna Mandruzzato

Department of Surgery, Oncology and Gastroenterology, Oncology and Immunology Section, University of Padova, Padova, Italy

Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy

Address for correspondence: Susanna Mandruzzato, Ph.D., Department of Surgery, Oncology and Gastroenterology, Oncology and Immunology Section, University of Padova, Via Gattamelata, 64, 35128, Padova, Italy. [email protected]Search for more papers by this author
Vincenzo Bronte

Vincenzo Bronte

Pathology and Diagnostics, Verona University Hospital, Verona, Italy

Search for more papers by this author
First published: 25 June 2014
Citations: 308

Abstract

The dynamic interplay between cancer and host immune system often affects the process of myelopoiesis. As a consequence, tumor-derived factors sustain the accumulation and functional differentiation of myeloid cells, including myeloid-derived suppressor cells (MDSCs), which can interfere with T cell–mediated responses. Since both the phenotype and mechanisms of action of MDSCs appear to be tumor-dependent, it is important not only to determine the presence of all MDSC subsets in each cancer patient, but also which MDSC subsets have clinical relevance in each tumor environment. In this review, we describe the differences between MDSC populations expanded within different tumor contexts and evaluate the prognostic significance of MDSC expansion in peripheral blood and within tumor masses of neoplastic patients.